IP Group

What IP Group does

IP Group PLC is a London-listed (LSE: IPO) intellectual property commercialisation and venture capital firm founded in 2001. The company identifies, invests in, and helps commercialise university spin-out businesses across the UK, Australia, and selectively the US, France, and Japan, with a portfolio spanning life sciences, deep tech, AI, clean energy, fusion and advanced manufacturing. As of 31 December 2025, total net asset value stood at £975.1m (110.4p per share), market capitalisation at £553.03m, and the firm held 101–250 employees operating from London with a wholly-owned regional entity, IP Group Australia.

The firm operates a holding-company business model rather than a product model: it sources opportunities through established university relationships (Oxford, Cambridge, Cardiff, Newcastle and others), takes equity stakes — including a 56.5% undiluted holding in Istesso and ~20.3% in Oxa — and provides capital, board-level support and commercialisation expertise through to exit. Revenue is realised through portfolio company exits (FY2025 cash proceeds £68.1m, including the Monolith sale to CoreWeave and Hinge Health's $3bn-valuation IPO), royalty and milestone payments (notably £128.2m from Pfizer's acquisition of Metsera), and revaluation gains. FY2025 returned to a £66.9m profit after a £207m loss the prior year, and the board has signalled a £250m+ exit pipeline for 2025–2027.

IP Group supplements balance-sheet investing with fund vehicles, most recently the Climate Catalyst Fund launched in March 2026 with Australia's Clean Energy Finance Corporation (target up to A$150m) targeting hard-to-abate industries. Governance saw a planned chair succession in 2026, with Michael Queen (formerly 3i Group) succeeding Sir Douglas Flint. The company rejected a £613.1m takeover bid from largest shareholder Railpen in June 2026, with the board citing a 37.2% discount to NAV; the rejection underscores both the contested valuation and IP Group's intention to remain independent and continue harvesting portfolio upside.

Name

IP Group

Legal name

IP Group PLC

Website

https://ipgroupplc.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

101–250 employees

Short description

IP Group PLC is a London-listed (LSE: IPO) intellectual property commercialisation and venture capital firm that invests in and supports university spin-out companies across life sciences, deep tech, AI, clean energy and advanced manufacturing in the UK, Australia and selectively the US, France and Japan.

Ownership category

akta.pro rank

Product category

Venture Capital and IP Commercialization

NAICS

Portfolio Management and Investment Advice (523940), Management of Companies and Enterprises (551)

SIC

Patent Owners & Lessors (6794)

akta.pro primary industry

IP Licensing, Transactions & Technology Transfer (BPAHAMAF)

akta.pro secondary industry

Private Credit — Royalty & IP-Backed Finance (FSAHAJAM)

Keywords

• Venture capital
• Intellectual property commercialization
• University spin-out funding
• Deep tech investment
• Life sciences investment

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Core offering

IP Group plc is a UK-listed intellectual property commercialization and venture capital firm that invests in and supports university spin-out companies across life sciences, deep tech, AI, clean energy, and advanced manufacturing. The firm deploys its own balance sheet capital alongside third-party fund vehicles (such as the Climate Catalyst Fund) to provide seed and Series A funding, commercialization expertise, and operational support to early-stage science and technology companies. Returns are generated through equity exits (IPOs and trade sales), royalty income, and dividends from portfolio companies.

Product overview

IP Group is a UK-listed venture capital and intellectual property commercialization firm that invests in science and technology companies, particularly university spin-outs. The company does not offer a unified product platform; rather, it manages a portfolio of investments across life sciences, deep tech, and clean energy sectors through its portfolio companies. IP Group provides capital, operational support, and intellectual property commercialization services to its portfolio companies rather than operating a direct-to-market product or service offering.

Differentiator

Problem solved

Functional benefit

Products and services

• IP Group Climate Catalyst Fund Cleantech investment fund targeting seed and Series A investments in companies addressing decarbonisation of hard-to-abate industries including cement, steel, chemicals, mineral processing, heavy transport, data centers, agriculture, and dispatchable energy. Available to portfolio companies and institutional co-investors.
• University Spin-out Investment Program Ongoing program providing seed and Series A capital plus commercialization support to spin-out businesses originating from UK, Australian, and other research universities. Targets companies across industrial processes, mineral processing, heavy transport, energy-efficient data centers, agriculture, and dispatchable energy.
• IP Commercialization Services Operational and strategic support services delivered alongside capital to university spin-out portfolio companies, providing commercialization expertise to bridge academic research to market-ready businesses across life sciences, deep tech, AI, clean energy, and advanced manufacturing.

Quantifiable outcome

• 13% NAV growth in 2025
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered minor.

• DHLminorStrategic or Co-development PartnerDHL is deploying Oxa's autonomous vehicle technology for industrial driving tasks in logistics facilities as a commercial customer.
• VantecminorStrategic or Co-development PartnerVantec is a customer deploying Oxa's industrial mobility automation technology in their operations.
• National Institute for Health and Care Research (NIHR)minorStrategic or Co-development PartnerNIHR is working with Istesso on the Phase II clinical trial (IST-03) of leramistat for sarcopenia, conducting the study at Newcastle University and Newcastle Hospitals.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Augmentum Fintech: UK-listed (LSE:AUGM) venture capital fund dedicated to fintech. Closely comparable UK-listed investment trust structure with NAV-driven valuation, public-market shareholders, and similar capital allocation cadence as IP Group.
• Oxford Science Enterprises: Oxford University-affiliated science and technology investment firm that builds and funds spin-out companies. Most directly comparable to IP Group given shared model of university spin-out commercialisation in life sciences and deep tech.
• Praetura Ventures: UK-based venture capital firm supporting early-stage and growth businesses across the UK, particularly in the North. Comparable in deploying venture capital into UK science and technology spin-outs and SMEs with similar ticket sizes and stage focus.
• Albion Capital: UK investment management group operating venture and growth capital trusts. Directly comparable as a UK-listed investment trust-style vehicle backing technology and life sciences businesses with similar investor base.
• Cambridge Innovation Capital: Investment firm focused on deep tech and life sciences businesses built on research from the University of Cambridge. Comparable investment thesis (Cambridge university spin-outs in biotech and deep tech) and similar long-duration hold model.
• Molten Ventures: UK-listed (LSE:GROW) venture capital firm investing in technology and consumer businesses. Directly comparable to IP Group as a publicly quoted UK VC with disclosed NAV and a portfolio management model serving public-market investors.
• Mercia Ventures: UK regional venture capital investor backing innovative technology and life sciences businesses, including university spin-outs. Operates as a direct co-investor alongside IP Group (e.g., Alesi Surgical £7m round) with overlapping origination channels.

Broad incumbents

• Octopus Ventures: One of the UK's largest VCs backing early-stage UK businesses across multiple sectors. Comparable as a major UK VC deploying institutional capital into similar UK technology and life sciences opportunities, though broader in scope than IP Group's science-focused specialisation.
• British Business Bank: UK government-backed economic development bank investing growth capital across UK SMEs, including life sciences and clean tech. Comparable in providing institutional scaling capital to UK innovation sectors, though with policy rather than returns-led mandate.

Regional players

• Northern Accelerator: Collaboration of seven North East England universities commercialising research through spin-out funding. Comparable as a UK university spin-out investor focused on specific regions, though more regional in scope than IP Group's UK-wide origination.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ip-group-plc
• Xx.com/IPGroupplc

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments305 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IP Group